Intravenous Iron Drugs Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 3.05 Billion |
| Market Size (2029) | USD 4.58 Billion |
| CAGR (2024 - 2029) | 8.50 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Intravenous Iron Drugs Market Analysis
The Intravenous Iron Drugs Market size is estimated at USD 3.05 billion in 2024, and is expected to reach USD 4.58 billion by 2029, growing at a CAGR of 8.5% during the forecast period (2024-2029).
During the pandemic, there is a slight decline in the intravenous iron drugs market due to the disruption of the supply chain and manufacturing process. But the market recovered soon and has grown subsequently, as there was a high demand for intravenous iron drugs, due to the increased risk of chronic kidney failure (CKD)-related anemia in COVID-19 patients. Furthermore, as per the article published by PubMed in August 2021, an older patient with numerous concomitant conditions who was hospitalized for COVID-19 was treated for iron deficient anemia with ferric carboxymaltose (Ferinjectâ, Vifor International). The medication caused the hemoglobin (Hb) to return to normal, the iron reserves to quickly restock, and the transferrin saturation to simultaneously improve. In cases of severe patients with diffuse coagulopathy, like the one in the present case, ferric carboxymaltose can be thought of as a viable option to treat anemia while a patient is being treated in a hospital for COVID-19 and avoid transfusion regimens. Hence as per the facts mentioned above, COVID-19 had a significant impact on the intravenous iron drugs market. However, as the pandemic has subsided, the studied the market is expected to have a stable growth during the forecast period of the study.
Certain factors driving the market growth include the increasing prevalence of target diseases such as chronic kidney disease-related anemia, irritable bowel syndrome, cancer-related anemia, disadvantages of oral iron drugs, and an increasingly aging population. For instance, as per the article published by PubMed in July 2022, a study was conducted which showed that IV iron for the treatment of cancer-induced anemia (CIA) reduces the need for red blood cells (RBC) transfusions and is not associated with adverse events. IV iron for the treatment of cancer-induced anemia should be considered in clinical practice.
Furthermore, government initiatives, research, and development in the field of IV iron drugs and the presence of competitors boost the market growth. For instance, in February 2021, The National Medical Products Administration (NMPA) in China approved Monofer (Ferric Derisomaltose) injection 100 mg/mL developed by Pharmacosmos. Monofer is an intravenous iron that is used in adult patients who have an intolerance to oral iron or unsatisfactory response to oral iron, or when there is a clinical need to administer iron quickly.
Apart from this, iron deficiency anemia is another common consequence of inflammatory bowel disease (IBD). For instance, according to an article published by PubMed Central in November 2022, iron deficiency (ID) and anemia in patients with inflammatory bowel disease (IBD) is often associated with a reduced quality of life. The article also stated that a study was conducted among a few IBD patients in the Netherlands, and it was found that the overall prevalence of anemia, iron deficiency and iron deficiency anemia was 18.0%, 43.4%, and 12.2%, respectively. Intravenous iron drugs are preferred for the treatment of IBD associated with iron deficiency anemia. Oral iron supplementation is the most frequent iron-deficient anemia treatment; however, it has been linked to gastro intestinal (GI) side effects such as constipation and bloating. Due to the lack of exposure to the intestinal lumen, intravenous iron drugs do not elicit gastro intestinal adverse effects. Therefore, chronic diseases such as CKD and IBD have resulted in persistent and prolonged anemia, fueling the growth of the intravenous iron drugs market.
Hence, due to the factors mentioned above such as the government initiatives, research, and development in the field of IV iron drugs, and increasing effectivity of IV iron drugs in cancer related anemia and irritable bowel disease, the studied market is anticipated to grow over the forecast period. However, adverse reactions associated with intravenous iron drugs restrain the market growth.
Intravenous Iron Drugs Market Trends
Ferric Carboxy Maltose Segment is Expected to Hold a Significant Market Share Over the Forecast Period
FCM (Ferric Carboxy Maltose) is a new parenteral iron drug that is the first of its kind to be approved by the United States FDA for quick and high-dose iron replenishment. It is used as an iron replacement drug for the treatment of iron deficiency anemia (IDA) in adult patients with oral iron intolerance, a poor response to oral iron, or non-dialysis-dependent chronic kidney disease.
Treatment for iron deficiency anemia with FCM aims to restore normal hemoglobin (Hb) levels, replenish iron storage, and normalize red cell levels. Other objectives include reducing anemia-related symptoms and improving health-related quality of life. Ferric carboxy maltose is a new therapy option that has a low risk of hypersensitivity events and is well tolerated at high doses besides being safe, effective, and cost-efficient compared to other available intravenous iron drug treatments.
Several studies have assured the safety and effectiveness of FCM over other intravenous iron drugs. For instance, as per the article published by PubMed Central in June 2022, FCM effectively, safely, and quickly treats patients with moderate-to-severe anemia in about 4 weeks. The clinical use of FCM in real-world scenarios is supported by doctors' favorable clinical impressions of its efficacy and safety. Hence such development and studies related to FCM are likely to boost the market growth over the forecast period. Moreover, FCM has been increasingly used in the treatment of cancer-related anemia, thus the increasing incidence of certain cancer types such as lymphoma, leukemia and multiple myeloma is also expected to boost the segment growth.
Furthermore, the presence of competitors, product launches, research, and development in the field of FCM fuels market growth. For instance, the clinical trial report published by the Journal of Marine Medical Society in October 2021, stated that an appropriate option for the treatment of postpartum anemia is ferric carboxymaltose (FCM), a more recent dextran-free iron formulation that permits single and higher doses (up to 1000 mg) of IV iron infusion. Furthermore, injection of FCM in the dose of 1000 mg given in a single dose before discharge in postpartum women helped in reducing postpartum anemia (PPA) without any significant adverse effects. Hence such substantial reports showing the advantages of FCM promotes market growth over the forecast period.
Therefore, factors such as best-in-class safety and efficacy, reduced dosing interval, improved clinical significance, increasing incidence of certain cancer types such as lymphoma, leukemia and multiple myeloma, and cost-effectiveness have fuelled the growth of the FCM segment in the intravenous iron drugs market.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period.
The rising prevalence of chronic kidney disease, gastrointestinal illnesses, and cancers in North America contributed to its regional dominance in the intravenous iron drugs market over the forecast period. Besides this, the approval and launch of new intravenous medications in the region have further propelled the market growth.
According to the data updated by CDC, in 2021, chronic kidney disease (CKD) affects 15% of adults in the United States. CKD affects more than one in seven persons in the United States accounting for approximately 37 million people in 2021. Age is also the biggest factor for CKD in the United States. For instance, CKD is more common in adults over 65 years old (38%) than in people 45-64 years old (12%) or 18-44 years old (18-44 years old) (6%). Anemia is a complication that affects most individuals with advanced CKD. The relative deficiency of erythropoietin production is the major driver of anemia. Iron deficiency contributes to impaired erythropoiesis in CKD patients. People who have CKD are prone to use intravenous iron products to improve their health and body iron levels. This propels market growth of intravenous iron drugs over the forecast period.
Furthermore, gastrointestinal illness such as irritable bowel disease (IBD) is also the most common complication in the United States and Canada. According to the Government of Canada, 260,000 Canadians were affected by IBD in 2021. Patients with IBD are commonly found to have iron deficiency anemia (IDA) secondary to chronic blood loss, and impaired iron absorption due to tissue inflammation. Hence the chance of using IV iron drugs in the studied area is boosted due to the high prevalence of such diseases.
Moreover, increasing product launches by key market players are also exhancing the market growth. For instance, in July 2021, Sandoz, one of the global leaders in generic and biosimilar medicines, launched the first generic high-dose intravenous iron, Ferumoxytol Injection, to treat the United States patients with iron deficiency anemia.
Hence, due to the aforementioned factors such as the increasing product launches, the high prevalence of diseases such as irritable bowel disease and chronic kidney disease, are expected to boost the growth of the market in the North American region during the forecast period of the study.
Intravenous Iron Drugs Industry Overview
The intravenous iron drugs market is consolidated and consists of a few players across the globe. In terms of market share, a few of the major players are currently dominating the market. Some of the companies that hold a significant market share are CSL Limited (Vifor Pharma Management Ltd.), AbbVie (Allergan), Covis Pharma GmbH (AMAG Pharmaceuticals, Inc), Sanofi, Pharmocos, Shield Therapeutics Rockwell Medical, American Regent among others.
Intravenous Iron Drugs Market Leaders
-
Sanofi
-
Pharmocosmos
-
AbbVie (Allergan)
-
Covis Pharma GmbH (AMAG Pharmaceuticals, Inc)
-
CSL Limited (Vifor Pharma Management Ltd.)
*Disclaimer: Major Players sorted in no particular order
Intravenous Iron Drugs Market News
- In November 2022, CSL Vifor and Fresenius Kabi received China's National Medical Products Administration (NMPA) approval for Ferinject, an intravenous iron therapy for the treatment of iron deficiency in adult patients for whom oral iron preparations are ineffective, oral iron preparations cannot be used or for whom there is a clinical need to deliver iron rapidly.
- In November 2022, a few NIH-funded researchers began a study of intravenous iron drug treatment for post-pregnancy anemia patients. The study will enroll an estimated 5,000 women in Bangladesh, India, Pakistan, the Democratic Republic of Congo, Kenya, Zambia, and Guatemala.
Intravenous Iron Drugs Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Target Diseases
4.2.2 Disadvantages of Oral Iron Drugs
4.3 Market Restraints
4.3.1 Adverse Reactions associated with Intravenous Iron Drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD Million)
5.1 By Product Type
5.1.1 Ferric Carboxymaltose
5.1.2 Iron Sucrose
5.1.3 Iron Dextran
5.1.4 Others
5.2 By Application
5.2.1 Chronic Kidney Disease
5.2.2 Irriable Bowel Disease
5.2.3 Cancer
5.2.4 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 CSL Limited (Vifor Pharma Management Ltd.)
6.1.2 Covis Pharma GmbH (AMAG Pharmaceuticals, Inc)
6.1.3 Daiichi Sankyo Company, Ltd.
6.1.4 Sanofi S.A.
6.1.5 Pharmacosmos A/S
6.1.6 Shield Therapeutics Plc
6.1.7 AbbVie (Allergan)
6.1.8 Rockwell Medical
6.1.9 Americal Reagent
6.1.10 Pfizer Inc.
6.1.11 Zydus Group
6.1.12 Keryx Biopharmaceuticals Inc
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Intravenous Iron Drugs Industry Segmentation
As per the scope of the report, intravenous iron drugs are iron supplement that is given through the intravenous route to compensate for iron losses in the blood in a certain clinical condition such as Chronic Kidney Disease (CKD), Intestinal Bowel Disease (IBD), cancer, among others to treat iron deficiency anemia. Intravenous iron drugs play a key role in treating diseases in nephrology, gastroenterology, oncology, critical care, gynecology, and others. The intravenous iron drugs market is segmented by Product Type (Ferric Carboxy maltose, Iron Sucrose, Iron Dextran, and Others), Applications (Chronic Kidney Disease, Irritable Bowel Syndrome, Cancer, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Product Type | |
| Ferric Carboxymaltose | |
| Iron Sucrose | |
| Iron Dextran | |
| Others |
| By Application | |
| Chronic Kidney Disease | |
| Irriable Bowel Disease | |
| Cancer | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Intravenous Iron Drugs Market Research FAQs
How big is the Intravenous Iron Drugs Market?
The Intravenous Iron Drugs Market size is expected to reach USD 3.05 billion in 2024 and grow at a CAGR of 8.5% to reach USD 4.58 billion by 2029.
What is the current Intravenous Iron Drugs Market size?
In 2024, the Intravenous Iron Drugs Market size is expected to reach USD 3.05 billion.
Who are the key players in Intravenous Iron Drugs Market?
Sanofi, Pharmocosmos, AbbVie (Allergan), Covis Pharma GmbH (AMAG Pharmaceuticals, Inc) and CSL Limited (Vifor Pharma Management Ltd.) are the major companies operating in the Intravenous Iron Drugs Market.
Which is the fastest growing region in Intravenous Iron Drugs Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Intravenous Iron Drugs Market?
In 2024, the North America accounts for the largest market share in Intravenous Iron Drugs Market.
What years does this Intravenous Iron Drugs Market cover, and what was the market size in 2023?
In 2023, the Intravenous Iron Drugs Market size was estimated at USD 2.79 billion. The report covers the Intravenous Iron Drugs Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Intravenous Iron Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Intravenous Iron Drugs Industry Report
Statistics for the 2023 Intravenous Iron Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Intravenous Iron Drugs analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
